HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC38A4
solute carrier family 38 member 4
Chromosome 12 · 12q13.11
NCBI Gene: 55089Ensembl: ENSG00000139209.17HGNC: HGNC:14679UniProt: Q969I6
25PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Transporter
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
neutral amino acid transportL-alanine import across plasma membraneprotein bindingneutral L-amino acid:sodium symporter activityscleritisiron metabolism diseasedyspepsialiver cancer
✦AI Summary

SLC38A4 encodes SNAT4, a sodium-dependent symporter that mediates electrogenic, pH-dependent cotransport of neutral amino acids (particularly glycine, alanine, serine, asparagine, and threonine) across the plasma membrane 123. The transporter preferentially recognizes smaller amino acids and tolerates partial lithium substitution for sodium 4. Clinically, SLC38A4 polymorphisms associate with glucose metabolism: the 1304 G>A SNP correlates with hyperglycemia in adults 5, while the 292 C>T SNP associates with elevated neonatal glucose 6. In placental physiology, SLC38A4 expression correlates with fetal growth—increased expression in macrosomic pregnancies and decreased expression in early preterm intrauterine growth restriction 78. SLC38A4 expression is sensitive to glucose deprivation and hypoxia in trophoblasts, suggesting nutrient-sensing functions 8. Beyond amino acid transport, SLC38A4 functions as a tumor suppressor in hepatocellular carcinoma, where its downregulation promotes proliferation via Wnt/β-catenin/MYC pathway activation 9. In pancreatic α-cells, SLC38A4 upregulation following glucagon receptor inhibition drives α-cell proliferation through mTORC1 activation 1011. These findings reveal SLC38A4's broader roles in glucose homeostasis, fetal development, and metabolic disease pathogenesis.

Sources cited
1
SLC38A4 cotransports neutral amino acids and sodium ions across the cell membrane
PMID: 11342143
2
SLC38A4 functions as a symporter of neutral amino acids and sodium
PMID: 19015196
3
SLC38A4 cotransports neutral amino acids and sodium; preferentially transports smaller amino acids
PMID: 33928121
4
SLC38A4 transport is electrogenic, pH-dependent, tolerates Li+ substitution for Na+, and shows preference for specific amino acids
PMID: 11414754
5
SLC38A4 292 C>T polymorphism associates with elevated glucose levels in full-term newborns
PMID: 33939685
6
SLC38A4 1304 G>A polymorphism associates with hyperglycemia in humans
PMID: 22945694
7
SLC38A4 expression correlates with fetal birth weight; elevated in macrosomia, unchanged in low birth weight
PMID: 22969887
8
SLC38A4 protein is downregulated in early preterm IUGR placentas; expression is sensitive to glucose deprivation and hypoxia
PMID: 36613847
9
SLC38A4 functions as a tumor suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC axis
PMID: 34274945
10
SLC38A4 expression increases in pancreatic α-cells after glucagon receptor inhibition via mTORC1 pathway
PMID: 30938753
11
Chronic hyperglycemia increases SLC38A4 expression in alpha cells, enhancing amino acid transport and sustaining mTORC1 activation
PMID: 37480416
Disease Associationsⓘ20
scleritisOpen Targets
0.33Weak
iron metabolism diseaseOpen Targets
0.32Weak
dyspepsiaOpen Targets
0.25Weak
liver cancerOpen Targets
0.08Suggestive
uterine fibroidOpen Targets
0.06Suggestive
fetal growth restrictionOpen Targets
0.05Suggestive
Uterine leiomyomaOpen Targets
0.05Suggestive
ulcerative colitisOpen Targets
0.04Suggestive
Varicose veinsOpen Targets
0.04Suggestive
vein disorderOpen Targets
0.04Suggestive
hepatocellular carcinomaOpen Targets
0.04Suggestive
neoplasmOpen Targets
0.03Suggestive
atrial fibrillationOpen Targets
0.03Suggestive
lymphatic system diseaseOpen Targets
0.03Suggestive
colorectal carcinomaOpen Targets
0.03Suggestive
epilepsyOpen Targets
0.03Suggestive
cancerOpen Targets
0.03Suggestive
nerve plexus diseaseOpen Targets
0.02Suggestive
Acute hepatic failureOpen Targets
0.02Suggestive
HypercholesterolemiaOpen Targets
0.02Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
SCN11AProtein interaction83%SFMBT2Protein interaction72%SLC6A15Shared pathway44%SLC6A12Shared pathway43%SLC6A18Shared pathway40%SLC6A19Shared pathway38%
Tissue Expression6 tissues
Liver
100%
Lung
0%
Heart
0%
Ovary
0%
Brain
0%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
SLC38A4SCN11ASFMBT2SLC6A15SLC6A12SLC6A18SLC6A19
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q969I6
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.51Moderately Constrained
pLIⓘ
0.96Intolerant
Observed/Expected LoF0.35 [0.24–0.51]
RankingsWhere SLC38A4 stands among ~20K protein-coding genes
  • #13,071of 20,598
    Most Researched25
  • #3,100of 17,882
    Most Constrained (LOEUF)0.51 · top quartile
Genes detectedSLC38A4
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Placental SLC38A4 gene polymorphisms 1304 G > A and 292 C > T, and their association with glucose > 95 mg/dl in normal weight full-term healthy newborns.
PMID: 33939685
Bol Med Hosp Infant Mex · 2021
1.00
2
Association of the polymorphisms 292 C>T and 1304 G>A in the SLC38A4 gene with hyperglycaemia.
PMID: 22945694
Diabetes Metab Res Rev · 2013
0.90
3
SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.
PMID: 34274945
Br J Cancer · 2021
0.80
4
Increased SLC38A4 Amino Acid Transporter Expression in Human Pancreatic α-Cells After Glucagon Receptor Inhibition.
PMID: 30938753
Endocrinology · 2019
0.70
5
SLC38A4 Amino Acid Transporter Expression Is Significantly Lower in Early Preterm Intrauterine Growth Restriction Complicated Placentas.
PMID: 36613847
Int J Mol Sci · 2022
0.60